/Investor DB

DCVC Bio — 2026 Investments

4 investments dated 2026 · listed companies and verified rows first · show all

Latuslatusbio.cominMay 2026 · $97M

Latus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise.

AI & Machine LearningBiotechDeep TechHealthtechPhiladelphia, US

Co-investorsBioAdvanceHatch BioFund8VCDCVC (Data Collective)GaingelsKorea Development Bank+1 more

Orca Bioorcabio.comin𝕏Apr 2026

Orca Bio develops allogeneic T-cell immunotherapies for high-risk blood cancers including acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome.

BiotechDigital HealthHealthtechMedical DevicesCalifornia, US

Ivan Dimov(Founder)inNathaniel Fernhoff(Founder)inJeroen Bekaert, PhD(Co-founder and President)Nate Fernhoff, PhD(Co-founder and Chief Executive Officer)inBob Lowsky(Founder)Everett Meyer(Founder)

Co-investors+ND Capital8VCDCVC (Data Collective)Dream Variation VenturesFelicis VenturesLightspeed Venture Partners+4 more

Sidewinder Therapeuticssidewinderbio.cominSeries B · Apr 2026 · $140M

Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.

BiotechHealthtechMedical DevicesSan Diego, US

Eric Murphy(Chief Executive Officer, Co-Founder, & Director)in

Co-investorsAstellas Venture Management LLCDCVC (Data Collective)Frazier Life SciencesLongwood FundNovartis Venture FundOrbiMed+2 more

Transcripta Biotranscriptabio.comin𝕏Jul 2026

Transcripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution.

AI & Machine LearningBiotechDeep Tech

Co-investorsBlueYard CapitalGaingelsJAZZ Venture PartnersARCH Venture PartnersInsight PartnersMayo Clinic Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.